The potential of glucagon-like peptide-1 receptor agonists in heart failure.

Further, in the FIGHT trial, which was the only trial sufficiently comprehensive to allow for the evaluation of hard outcomes, even though the HR was above 1 for the composite endpoint of hospital admission due to HF, the treatment effect did not reach statistical significance (HR [liraglutide vs. placebo at 6 months] 1.3, 95%CI 0.89–1.88) in 300 people with HF, with and without type 2 diabetes and with recent decompensation ( Margulies et al., 2016 ).

also in 111,027 other papers